Initiator Pharma A/S (INIT) today announces that individuals in the board and managemet exercise a total of 434 197 warrants for subscription of new shares, raising approx 1,9 SEKM in proceeds to the company. The number of issued shares increases by 434 197 and the share capital increases by 45 590,685 DKK.
The warrants have been exercised under the warrant program 2017/2020, approved by the Annual General Meeting of 16 May 2017, comprising 434,197 warrants and has been fully exercised according to the below distribution:
[][][][]
Individual[1] Position Excercised Share holding Warrants Total shares
warrants after exercise after and warrants
exercise[2]
Magnus Mondee Chairman 78 155 120 036 147 627 267 663
Persson
Claus Elsborg CEO 86 841 779 579 178 019 957 598
Olesen
Torgeir Vaage CFO 78 155 161 701 151 967 313 668
Mikael S. CDO 78 155 618 191 169 334 787 525
Thomsen
Ulf Simonsen CMO 47 762 585 200 104 208 689 408
Dan Peters CTO 47 762 1 036 711 78 162 1 114 873
Henrik Moltke Board 17 367 59 248 39 077 98 325
member
Total 434 197 3 360 666 868 394 4 229 060
[1 ] Personally
or through
wholle
controlled
holding company
[2] Warrant
program
2018/2020 and
2019/2021
The increase in share capital has been executed without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of SEK 4.34 per share, of nominally DKK 0.105. Proceeds to the company are SEK 1 884 414,98. The new shares are freely transferable and will after registration be tradable on Spotlight Stock Market. The new shares shall give rights to dividends and other rights in relation to the company.
Initiator Pharma's current share capital amounts to DKK 2 431 503,69 and will after registration of the capital increase be DKK 2 477 094,375. The current number of shares in the company is 23,157,178 and will after the registration of the capital increase be 23 591 375.
For more information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone number: +45 6126 0035
E-mail: [email protected]
This information is the type of information that Initiator Pharma (Ltd.) is obligated to publish pursuant to the EU Market Abuse Regulation. The information was provided by the contact person above, to be published on 23rd December 2019.
About Initiator Pharma
Initiator Pharma is a biotechnology company based in Aarhus, Denmark. The company's main asset, IPED2015, is a candidate drug intended for patients with erectile dysfunction. The treatment is expected to improve the quality of life for a growing number of patients who are not responding to or cannot be treated with existing drugs on the market. Read more on www.initiatorpharma.com.
About erectile dysfunction
ED is a sexual dysfunction characterised by the inability to achieve or maintain an erection during sexual intercourse. More than 150 million men around the world suffer from ED; a number that is expected to increase to more than 320 million by 2025 due to an ageing population and an increased incidence of lifestyle illnesses such as diabetes. ED entails an impaired quality of life in patients due to various psychosocial factors, such as low self-esteem, depression, sadness, anger, frustration, anxiety and relationship problems (1, 2, 3).
1. Shabsigh R, et al. (1998) Increased incidence of depressive symptoms in men with erectile dysfunction. Urology52(5):848-852.
2. Mccabe MP, Althof SE (2014) A systematic review of the psychosocial outcomes associated with erectile dysfunction: Does the impact of erectile dysfunction extend beyond a man's inability to have sex? J Sex Med11(2):347-363.
3. Nguyen HMT, Gabrielson AT, Hellstrom WJG (2017) Erectile Dysfunction in Young Men-A Review of the Prevalence and Risk Factors. Sex Med Rev5(4):508-520.